Harmony Biosciences Holdings Inc (HRMY) FinancialsHRMYHarmony Biosciences Holdings Inc

Evaluating the bottom line, Harmony Biosciences Holdings, Inc. maintains a gross margin of 75.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 34.18%, while the net margin is 28.87%. These profitability ratios, combined with a Return on Equity (ROE) of 20.46%, provide a clear picture of how effectively HRMY converts its operational activities into shareholder value.

In the context of the broader market, HRMY competes directly with industry leaders such as SLS and PBH. With a market capitalization of $2.31B, it holds a significant position in the sector. When comparing efficiency, HRMY's gross margin of 75.81% stands against SLS's N/A and PBH's 49.11%. Such benchmarking helps identify whether Harmony Biosciences Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Harmony has shown strong revenue growth, with Q2 2026 revenue at $261.28 million and a net income of $75.43 million, reflecting a gross margin of 75.81%. The company has consistently maintained a high gross margin, averaging around 75% over recent quarters, which indicates solid profitability.